Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Tubulis

Tubulis Announces Second Closing of Series C Bringing Total Raised to €344M (US $401M)
From Tubulis
Via Business Wire
Tubulis Presents First Clinical Data from Phase I/IIa Trial for TUB-040 in Platinum-Resistant Ovarian Cancer (PROC) at ESMO 2025
From Tubulis
Via Business Wire
Tubulis Raises €308 Million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline
From Tubulis
Via Business Wire
Tubulis to Present First Phase I/IIa Trial Data for ADC Candidate TUB-040 in Platinum-Resistant Ovarian Cancer in Late-Breaking Oral Presentation at ESMO 2025
From Tubulis
Via Business Wire
Tubulis Strengthens Leadership Team with Appointment of Halley Gilbert as Chief Legal and Operating Officer
From Tubulis
Via Business Wire
Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.
From Tubulis
Via Business Wire
Tubulis Announces First Patient Dosed in Phase I/IIa Trial Evaluating ADC TUB-030 in Advanced Solid Tumors
From Tubulis
Via Business Wire
Tubulis to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Tubulis
Via Business Wire
Fierce Biotech Names Tubulis a "Fierce 15" Biotech Company of 2024
From Tubulis
Via Business Wire
Tubulis Receives FDA Fast Track Designation for Antibody-Drug Conjugate Candidate TUB-040 in Platinum-resistant Ovarian Cancer
From Tubulis
Via Business Wire
Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma
From Tubulis
Via Business Wire
Tubulis Presents Preclinical Data for Solid Tumor Targeting ADC Candidates TUB-030 and TUB-040 Demonstrating Superior Efficacy Profile and a Wide Therapeutic Window at the AACR Annual Meeting 2024
From Tubulis
Via Business Wire
Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline
From Tubulis
Via Business Wire
Tubulis to Present Preclinical Proof-of-Concept Data for Two Lead ADC Candidates Targeting Solid Tumors at the AACR Annual Meeting 2024
From Tubulis
Via Business Wire
Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients
From Tubulis
Via Business Wire
Tubulis Appoints Seasoned ADC Expert Björn Hock as Chief Development Officer
From Tubulis
Via Business Wire
Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies
From Tubulis
Via Business Wire
Tubulis Establishes Scientific Advisory Board with Leading ADC Drug Development and Oncology Experts
From Tubulis
Via Business Wire
Tubulis Appoints Christian Grøndahl as Independent Chairman to Lead Supervisory Board
From Tubulis
Via Business Wire
Tubulis appoints Günter Fingerle-Rowson as Chief Medical Officer to lead the clinical development of its new generation of ADCs
From Tubulis
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.